TCGA-63-A5MW-01A-11R-A26W-07
— · cohortMD1
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- cohortMD1
- subtype
- cohortMD1
- age_years
- 76
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- E2F_TARGETS+0.320
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.320
- WNT_BETA_CATENIN_SIGNALING+0.310
- G2M_CHECKPOINT+0.280
- ANGIOGENESIS+0.230
- HEDGEHOG_SIGNALING+0.230
- MYC_TARGETS_V2+0.170
- SPERMATOGENESIS+0.170
- KRAS_SIGNALING_DN+0.150
- PANCREAS_BETA_CELLS+0.140
Top 10 suppressed
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.580
- INTERFERON_ALPHA_RESPONSE-0.520
- INTERFERON_GAMMA_RESPONSE-0.510
- ALLOGRAFT_REJECTION-0.480
- INFLAMMATORY_RESPONSE-0.460
- OXIDATIVE_PHOSPHORYLATION-0.450
- COMPLEMENT-0.430
- FATTY_ACID_METABOLISM-0.420
- IL6_JAK_STAT3_SIGNALING-0.410
- MTORC1_SIGNALING-0.410
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
7 twins match this tumor's tissue · 3 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | SRR6013547 | — | cohortMD1 | 0.924 |
| 2 | a9e8922f-fd6c-412d-85f5-40f5ea9b5455 | — | — | 0.914 |
| 3 | BS_44A3ES23 | medulloblastoma | — | 0.908 |
| 4 | SRR2932838 | — | — | 0.897 |
| 5 | s0122214 | — | — | 0.896 |
| 6 | TCGA-AC-A2QH-01B-04R-A22O-07 | — | D | 0.882 |
| 7 | BS_4E1G7E3G | ATRT | — | 0.878 |
| 8 | C3N-02435 | — | cohortSQ1 | 0.877 |
| 9 | s_150203_4b | EPN | Posterior Fossa EPN | 0.874 |
| 10 | MNG459 | — | — | 0.872 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 14 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| E2F_TARGETS | 0.320 | Inavolisib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.320 | Inavolisib | — uncovered |
| WNT_BETA_CATENIN_SIGNALING | 0.310 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.280 | Inavolisib | — uncovered |
| ANGIOGENESIS | 0.230 | Remibrutinib | — uncovered |
| HEDGEHOG_SIGNALING | 0.230 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.170 | Idelalisib | — uncovered |
| SPERMATOGENESIS | 0.170 | Inavolisib | — uncovered |
| KRAS_SIGNALING_DN | 0.150 | Remibrutinib | — uncovered |
| PANCREAS_BETA_CELLS | 0.140 | Cobimetinib | — uncovered |
| UV_RESPONSE_DN | 0.130 | Inavolisib | — uncovered |
| MITOTIC_SPINDLE | 0.090 | Inavolisib | — uncovered |
| DNA_REPAIR | 0.050 | Idelalisib | — uncovered |
| MYOGENESIS | 0.030 | Inavolisib | — uncovered |